The SLC34 family of sodium-dependent phosphate transporters by Wagner, Carsten A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
The SLC34 family of sodium-dependent phosphate transporters
Wagner, Carsten A; Hernando, Nati; Forster, Ian C; Biber, Jürg
Abstract: The SLC34 family of sodium-driven phosphate cotransporters comprises three members: NaPi-
IIa (SLC34A1), NaPi-IIb (SLC34A2), and NaPi-IIc (SLC34A3). These transporters mediate the translo-
cation of divalent inorganic phosphate (HPO4 (2-)) together with two (NaPi-IIc) or three sodium ions
(NaPi-IIa and NaPi-IIb), respectively. Consequently, phosphate transport by NaPi-IIa and NaPi-IIb is
electrogenic. NaPi-IIa and NaPi-IIc are predominantly expressed in the brush border membrane of the
proximal tubule, whereas NaPi-IIb is found in many more organs including the small intestine, lung, liver,
and testis. The abundance and activity of these transporters are mostly regulated by changes in their
expression at the cell surface and are determined by interactions with proteins involved in scaffolding,
trafficking, or intracellular signaling. All three transporters are highly regulated by factors including di-
etary phosphate status, hormones like parathyroid hormone, 1,25-OH2 vitamin D3 or FGF23, electrolyte,
and acid-base status. The physiological relevance of the three members of the SLC34 family is underlined
by rare Mendelian disorders causing phosphaturia, hypophosphatemia, or ectopic organ calcifications.
DOI: 10.1007/s00424-013-1418-6
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-88688
Accepted Version
Originally published at:
Wagner, Carsten A; Hernando, Nati; Forster, Ian C; Biber, Jürg (2014). The SLC34 family of sodium-
dependent phosphate transporters. Pflügers Archiv : European Journal of Physiology, 466(1):139-153.
DOI: 10.1007/s00424-013-1418-6
1 
 
 
 
 
 
 
 
 
The SLC34 family of sodium-dependent phosphate transporters 
 
Carsten A. Wagner, Nati Hernando, Ian C. Forster, Jürg Biber 
Institute of Physiology, University of Zurich, Switzerland 
 
Corresponding author 
Carsten A. Wagner 
Institute of Physiology 
University of Zurich 
Winterthurerstrasse 190 
CH-8057 Zurich 
Switzerland 
Phone: +41-44-63 55023 
Fax: +41-44-63 56814 
Email: Wagnerca@access.uzh.ch 
 
 
 
 
 
2 
 
 
 
ABSTRACT 
The SLC34 family of sodium-driven phosphate cotransporters comprises three 
members: NaPi-IIa (SLC34A1), NaPi-IIb (SLC34A2), and NaPi-IIc (SLC34A3). These 
transporters mediate the translocation of divalent inorganic phosphate (HPO42-) 
together with two (NaPi-IIc) or three sodium ions (NaPi-IIa and NaPi-IIb), 
respectively. Consequently, phosphate transport by NaPi-IIa and NaPi-IIb is 
electrogenic. NaPi-IIa and NaPi-IIc are predominantely expressed in the brush border 
membrane of the proximal tubule, whereas NaPi-IIb is found in many more organs 
including the small intestine, lung, liver, and testis. The abundance and activity of 
these transporters is mostly regulated by changes in their expression at the cell 
surface and is determined by interactions with proteins involved in scaffolding, 
trafficking or intracellular signaling. All three transporters are highly regulated by 
factors including dietary phosphate status, hormones like parathyroid hormone, 1,25-
OH2 vitamin D3 or FGF23, electrolyte and acid-base status. The physiological 
relevance of the three members of the SLC34 family is underlined by rare Mendelian 
disorders causing phosphaturia, hypophosphatemia, or ectopic organ calcifications. 
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Phosphate homeostasis 
Essential role of phosphate 
Phosphate is the third most abundant anion in the body and required for a 
variety of fundamental biologic processes.  Inorganic phosphate is essential for 
bioenergetics (ATP, GTP), metabolic regulation (e.g. in glycolysis or oxidative 
phosphorylation), intracellular signaling pathways, cell proliferation (as part of the 
DNA and RNA), and for structures such as bones and membranes [26,25]. 
Phosphate contributes also to acid-base balance as buffer in blood and in urine.  
Approximately 85% of total body phosphate is accumulated in bone and teeth, about 
14 % is in soft tissues such as skeletal muscle and erythrocytes and only 1% 
circulates as free phosphate in extracellular fluids. The concentration of intracellular 
inorganic phosphate may be in the range of 0.7 – 2.5 mM as determined by 31P-NMR 
and chemical analyses [51]. Extracellular concentrations of inorganic phosphate vary 
between 0.8 and 1.2 mM in humans. In plasma, phosphate exists in both the 
monovalent and the divalent form. Based on the pK-value of 6.8, at blood pH of 7.4, 
72 % of plasma phosphate is present in the divalent (HPO42-) and 28 % is present in 
the monovalent (H2PO4-) form.  
 The extracellular concentration of phosphate depends to a large extent on 
mechanisms that control renal excretion of phosphate. Renal handling of phosphate, 
and to a lesser extent gastrointestinal absorption of phosphate, is controlled by 
complex regulatory networks that involve several organs and several endocrine 
factors [20,38,88,96,98].  
 Deviations from normal serum phosphate concentrations cause severe clinical 
disorders. Even slight chronic elevations have been associated with increased rates 
of death due to cardiovascular complications  that are common among patients with 
chronic kidney disease [131-132,32,115]. On the other hand, prolonged 
hypophosphatemia, caused by e.g. malabsorption, renal phosphate losses or 
inherited disorders such as X-linked hypophosphatemia [18], results in symptoms 
such as osteomalacia, hypercalciuria and bone demineralization [29].  
 
 
 
4 
 
Intestinal phosphate absorption 
 Organic phosphate ingested in foods is hydrolyzed in the gastrointestinal tract 
releasing inorganic phosphate. Phosphate absorption along the gastrointestinal tract 
is mediated by  two pathways, a transcellular absorptive component, that involves 
SLC34 and SLC20 sodium-dependent phosphate cotransporters [54,96,118] and a 
concentration- or load- dependent absorptive component that may permeate the 
paracellular route, that, however, is poorly characterized. Together these two 
processes results in an overall fractional absorption of phosphate that ranges 
between 65% and 70% of the amount ingested. Notably, segmental distribution of 
absorption of phosphate varies among different species. In humans and rats most of 
the ingested phosphate is absorbed in duodenum and jejunum, whereas in mice, 
most of the phosphate absorption occurs in the ileum [96-97,114]. The role of the 
colon is uncertain.  
 Intestinal absorption of phosphate is regulated and adapts to dietary 
phosphate intake as well as to acid-base status and various hormones such as 1,25-
OH2 vitamin D3 or glucocorticoids (see below, regulation of NaPi-IIb). 
 
Renal phosphate handling 
  Phosphate is almost freely filtered by the glomerulus and subsequently 
reabsorbed along the nephron. The extent of reabsorption depends on dietary intake 
and a variety of other factors (see below). For the average diet, fractional excretion of 
phosphate in adults is in the range of 10 – 30 % of the filtered load. There is no 
evidence for secretion of phosphate. The main site of phosphate reabsorption is the 
proximal tubule, whether and to which extent more distal segments contribute to 
phosphate reabsorption has not been fully clarified [21,71-72]. In rodents, the early 
proximal segments have higher phosphate transport rates and juxtamedullary 
nephrons are more active than superficial nephrons [21,103-104]. 
Renal phosphate handling is highly regulated by many factors including dietary 
phosphate intake, acid-base homeostasis, electrolyte status (e.g. hypokalemia), and 
a variety of hormones. The renal excretion of phosphate is increased by high dietary 
intake of phosphate, during acidosis, hypokalemia, by parathyroid hormone (PTH), 
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1,25-OH2-vitamin D3, fibroblast growth factor 23 (FGF23), dopamine, or 
glucocorticoids. In contrast, increased renal phosphate reabsorption occurs due to 
low dietary phosphate intake, during alkalosis, or stimulated by insulin, insulin-like 
growth factor 1(IGF1), 1,25-OH2-vitamind D3, and thyroid hormone [103-
104,21,17,27]. 
 
The SLC34 family of sodium-dependent phosphate transporters 
NaPi-IIa (SLC34A1) 
 The human NaPi-IIa isoform comprises 639 amino acids. Rat and human 
NaPi-II cDNAs were first isolated by expression cloning  [93]. NaPi-IIa is 
predominantely expressed in kidney and localizes to the apical brush border 
membrane of the proximal tubule (Fig. 1)[34]. Expression is higher in early 
convoluted proximal tubules (S1 segments) and in juxtamedullary nephrons but 
spreads to the late proximal tubule (S2/S3 segments) and to superficial nephrons 
during phosphate depletion [89]. NaPi-IIa mRNA has also been detected in bone and 
brain but protein expression has not been confirmed.  
 
NaPi-IIb (SLC34A2) 
NaPi-IIb is a protein of 689 amino acids in humans and its mRNA has been 
detected in many  organs including lungs, testis, salivary gland, thyroid gland, small 
intestine, liver, mammary gland, uterus [68]. In small intestine, NaPi-IIb is expressed 
at the luminal brush border membrane, in rats and humans in the duodenum and 
jejunum, whereas in mice mostly in ileum [68,105,114]. 
 
NaPi-IIc (SLC34A3) 
 Human NaPi-IIc comprises 599 amino acids and like NaPi-IIa is mostly 
expressed in kidney. In kidney, NaPi-IIc is found in the brush border membrane of the 
early proximal tubule (S1 segment) of juxtamedullary nephrons and is absent from 
other portions of the proximal nephron (Fig. 1). During phosphate depletion, NaPi-IIc 
protein is also detected in the early proximal tubule of superficial nephrons 
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[24,112,121]. NaPi-IIc may also be expressed in bone but its function there has not 
been elucidated [125]. 
 
 
Structural and functional characteristics of SLC34 transporters 
 Transport mechanism and kinetic characteristics of SLC34 proteins 
 
The three SLC34 isoforms (NaPi-IIa, b,c) are selective for divalent Pi (HPO42-) 
[8,49] and use the inwardly directed Na+ electrochemical gradient to catalyse uphill 
movement of Pi. Although Na+ and Pi are the preferred substrates, cation 
replacement studies have established that Li+ can partly substitute for Na+ to drive Pi 
transport, albeit at a significantly lower rate [4]. Transport by NaPi-IIb of the 
phosphate mimetic arsenate has been demonstrated [138] and given its intestinal 
localisation this may have relevance for providing a potential route for arsenate 
accumulation, for example in aquatic species [16]. Transport capacity of SLC34 
proteins is also strongly dependent on external pH. As pH defines the 
monovalent/divalent Pi distribution in the extracellular compartment it may, for 
example, influence transport rates for NaPi-IIa and NaPi-IIc along the proximal 
tubule. Protons can also directly modulate the transport kinetics by competing with 
Na+ binding and by modifying the apparent rate constants associated with specific 
kinetic steps in the transport cycle [45].  
The SLC34 isoforms display similar apparent substrate affinity constants of 
≤100 µM and ∼40 mM for Pi and Na+ respectively, at pH 7.4. The transporters 
probably function close to their maximum rates at least in the initial segment of the 
renal proximal tubule, given that these apparent affinities are generally well below the 
typical concentrations found under normal physiological conditions in the intestine 
and renal proximal tubule. The apparent affinity for Pi is somewhat larger for the 
mammalian NaPi-IIb compared with the other isoforms (∼10 µM) and this may 
partially compensate for the reduced availability of divalent Pi in a low pH 
environment [47,50]. 
The salient functional feature that distinguishes the three isoforms is whether 
or not net charge movement accompanies cotransport. NaPi-IIa and NaPi-IIb are 
electrogenic and translocate one net positive charge per transport cycle. They 
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mediate transport with a 3:1 Na+:Pi stoichiometry [49]. Importantly, their transport 
rates are a strong function of membrane potential.  In contrast, NaPi-IIc is 
electroneutral with no net charge translocation and its transport kinetics are 
insensitive to membrane potential. It mediates transport with a 2:1 stoichiometry 
[8,122]. The difference in stoichiometries between these isoforms means that the 
theoretical Pi concentrating capacity is approximately 100-fold higher for NaPi-IIa/b 
compared with NaPi-IIc, at the cost of a 10-fold greater inward flux of Na+ ions, 
together with net charge movement, both of which must be compensated by the cell 
through the action of the Na+/K+-ATPase. 
The transport process for the electrogenic isoforms can be described as a 
sequence of partial reactions between states that correspond to unique 
conformations of the protein (Fig. 2). This model is consistent with an alternating 
access transport mechanism, whereby substrate binding can occur from either the 
extra- or intra-cellular medium, but not from both simultaneously. The development of 
this model for the electrogenic NaPi-IIa,b and its extension to include NaPi-IIc has 
relied on several experimental approaches based on applying the voltage clamp 
technique to single Xenopus oocytes that heterologously express the specific 
isoform. This technique allows control of a key driving force for transport, membrane 
potential. Moreover, assays in which both substrate flux (Na+, Pi) and net charge 
translocation are measured simultaneously on the same oocyte have allowed a 
definitive determination of stoichiometry and specification of the preferred Pi species 
to be made [49]. Importantly, these assays also confirm the validity of using Pi-
induced membrane current as a measure of transport activity. Using steady-state and 
presteady-state kinetic analysis, electrogenic partial reactions were identified and 
apparent substrate affinities, turnover rate, pH dependence and the substrate binding 
order were determined (for review see [47]).  
Presteady-state charge relaxations, which result from rapid changes in 
membrane potential, have proven indispensable to our understanding of the 
transduction of membrane potential as a transport driving force. They are ubiquitous 
property of many electrogenic cation driven symport systems (e.g. SGLT1 [63,91], 
GAT1 [101], EAAT [58]) and provided the first indirect evidence that conformational 
changes occur as the protein moves from one state to another in response to 
changes in membrane potential. For NaPi-IIa/b, the transport voltage dependence of 
arises intrinsically from the proteins themselves that adopt favored orientations 
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(outward facing or inward facing, Fig. 2), together with Na+ ion movement to binding 
sites within the transmembrane electric field (for review see [47]). From 
measurements of the total charge displacement as a function of membrane potential, 
estimates of an effective valence per transporter can be obtained, amounting to 0.3-
0.4 for the intrinsic carrier and 0.6-0.7 for the carrier with Na+ bound.    
By substituting cysteines at functionally important sites and labeling these 
covalently with fluorophores, it was established that 2 Na+ ions bind sequentially and 
cooperatively before Pi and a 3rd Na+ binding transition precedes the reorientation of 
the fully loaded carrier (see Fig. 2) ([142,53]. This conclusion was supported by a 
detailed cation substitution study in which presteady-state analysis identified the Li+ 
interaction site as corresponding to the 1st Na+ ion binding site [4]. The apparent 
affinity for Na+ is determined largely by the first Na+ interactions, whereas the 3rd Na+ 
is a strong determinant of the transport turnover rate. Presteady state kinetic analysis 
can also be used to estimate the functional expression from the ratio of total mobile 
change to effective valence. Moreover, by combining with steady-state 
electrophysiological measurements, the transport turnover rate can be estimated. For 
selected electrogenic NaPi-IIa/b this was typically <100 s-1 and may vary among 
isoforms and species [50]. 
 
The electroneutral NaPi-IIc transport mechanism differs from the electrogenic 
scheme in that the 1st Na+ ion to bind to the outward facing empty carrier is not 
transported (Fig. 2). Thus, for NaPi-IIc, three Na+ ions bind, but only two are 
translocated and released to the cytosol [53]. For the electrogenic isoforms, the 1st 
Na+ ion is thought to contribute to an uncoupled leak in the absence Pi [3]. Although 
we propose that Li+ can also compete with Na+ for occupancy at the first cation 
binding site and that in the cotransport mode Li+ ions can indeed translocate, their 
contribution to the leak current has not been demonstrated. This “uniport” mode is not 
detected in NaPi-IIc but when electrogenicity is restored through mutagenesis, the 
leak mode returns, as evidenced by a change in holding current induced by the 
inhibitor phosphonoformic acid (PFA), a SLC34 inhibitor [8]. Interestingly, naturally 
occurring mutations in NaPi-IIc were shown to result in a significant Na+-leak [73]. 
Despite considerable progress in characterizing NaPi-II proteins at the mechanistic 
level, two areas still deserve attention. First, we are lacking concrete insight into the 
cytosolic release of substrates, principally because of the experimental limitations of 
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the intact Xenopus oocyte preparation. In one study, NaPi-IIc expressing oocytes 
were preloaded with tracer substrate and by establishing an outward driving force, 
reverse transport of Pi was demonstrated in agreement with the kinetic scheme [53]. 
Recently evidence based on presteady-state analysis of the kinetics of the 
electroneutral NaPi-IIc, which was modified by mutagenesis to exhibit electrogenic 
behavior [8], suggests that the last step in the transport cycle is indeed the cytosolic 
release of one Na+ ion [110]. This also agrees with earlier studies on the uncoupled 
Na+ leak mode [4] in which it was proposed that the leak mode is essentially an 
uniporter involving the empty carrier and two Na+ bound states [43]. Further insight 
will only be obtained using patch clamp or cut-open oocyte techniques to controlling 
the cytosol composition. 
Second, there is a lack of specific high affinity inhibitors for SLC34 proteins. 
PFA acts as a competitive inhibitor for all isoforms [135,137] and is the compound 
readily available. However its apparent inhibition constant is relatively large [90] 
(typically 1 mM (NaPi-IIa), 0.16 mM (NaPi-IIb) and 0.9 mM (NaPi-IIc) [136]) and at 
high concentrations PFA can induce non-specific leak in the cell membrane (I. C. 
Forster, unpublished observations). Other commercially synthesized substances with 
greater efficacies, show mixed competitive and non-competitive behavior (e.g. JTP-
59557, Japan Tobacco [99], see also [146]). Having access to specific and high-
affinity inhibitors would obviously have considerable potential for control of dietary Pi 
intake, for which NaPi-IIb is a clinical target. 
 
Structure and structure-function relationships 
 
SLC34 proteins are a unique class of membrane transport proteins and share 
no obvious homology with the other solute carrier families, even at the bacterial level. 
At present a 3-D structure of the mammalian SLC34 proteins or their bacterial 
homologs is lacking, and therefore all structural information has been derived from 
indirect biophysical and biochemical studies on wild-type and engineered mutations, 
for review see [47]. NaPi-IIa was shown to be a functional monomer [82], however 
indirect evidence indicates dimeric or tetrameric structures in the membrane 
[46,59,56]. The primary sequences of the mammalian isoforms vary from 599 amino 
acids (NaPi-IIc) to ∼640 amino acids (NaPi-IIa and NaPi-IIb). Sequence differences 
appear mainly in the intracellular C- and N-terminal regions and the large 
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extracellular loop which contains 2 N-glycosylation sites and a disulfide bridge that 
links the two halves of the protein (Fig. 3).The proposed secondary topology of the 
eukaryotic isoforms comprises 8 transmembrane domains (TMDs) and two opposed 
reentrant loop domains that most likely contain short α-helical motifs. This model 
incorporates predictions from biochemical and biophysical studies including epitope 
labeling, cysteine scanning mutagenesis and in vitro glycosylation assays (for review 
see: [44,46,48,139]. The C-terminal region is important for targeting, hormonal 
regulation and protein-protein interactions. For example, the TRL motif in the C-
terminal plays a role as a PDZ binding motif [67,77], and a KR motif located in an 
intracellular linker region (Fig. 3) is critical for parathyroid hormone (PTH) sensitivity 
[76]. Of note from the transport function perspective is the signature inverted repeat 
motif that is conserved among SLC34 isoforms and homologs in all phyla [147]. 
Cysteine substitution studies (see below) confirm the functional role of these repeats 
in defining the transport pathway [48,52]. Given that similar motifs are found in the 3-
D structures of transporters with identified architecture, e.g. [1,42,120], they most 
likely contain substrate coordination sites for NaPi-II proteins also. Thus, all SLC34 
proteins, including bacterial homologs, are expected to have similar functional core 
elements comprising TMD’s 2-10 (Fig. 3). 
Cysteine scanning mutagenesis, in which cysteines are substituted at 
potentially functionally important sites in the protein and the accessibility by thiol-
reactive reagents (methanesulfonates) is determined (e.g. [79] ) has been applied 
extensively to SLC34 proteins (for review see [47-48] ) (see Fig. 3). These studies 
have yielded both structural information as well as mechanistic insights. Substitutions 
have been made at sites in the predicted re-entrant regions and accessibility studies 
confirm the reentrant topology [83,87]. Accessibility of some sites is strongly 
membrane potential and substrate dependent, confirming that the protein 
conformation is sensitive to these variables [86,142] and cross-linking studies 
suggest that the two reentrant regions indeed associate [52]. Finally, new insights 
into the transport mechanism and structure-function relationships have been gained 
by covalently linking fluorophores to engineered cysteines. The change in 
fluorescence emission in response to change in membrane potential and external 
substrate is an indication of specific conformational changes affecting the 
microenvironment of the fluorophore. In addition to establishing the cation binding 
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order [142,53,110], they also provide compelling evidence of reciprocal movements 
of the two halves of the protein during the transport cycle [141]. 
Finally, insight into the molecular determinants of functional differences 
between isoforms can be gained by comparing sequences and identifying critical 
amino acids. For example, the electroneutral NaPi-IIc [122] was used to elucidate the 
molecular determinants of electrogenicity. Three regions were highlighted that differ 
significantly in amino acid sequence between electrogenic and electroneutral 
isoforms. In one of these regions 3 critical amino acids were found by mutagenesis 
that are conserved in all electrogenic isoforms. Their presence confers electrogenic 
Na+ interactions and transport-dependent charge translocation [8] and recently it was 
shown that this “re-engineering” of electrogenicity has most likely only restored 
charge movement to the empty carrier and internal release of one Na+ ion [110].  
 
Regulation of SLC34 transporters 
Interacting proteins 
           In vivo and in vitro experiments have shown that NaPi-IIa physically interacts 
with several proteins in the renal brush border membrane, and that some of these 
interactions have effects on the expression as well as the regulation of the 
cotransporter. Most of the known interactions are PDZ (PSD-95, Disc-large, ZO-1)-
based. The C-terminal residues of NaPi-IIa (TRL) constitute a PDZ-binding domain 
that is engaged in association with the PDZ domains of the four members of the 
NHERF (NHE3 regulatory factor) family [57,56], as well as with Shank2E [100] 
(Figure 4).  
          Binding to NHERF1 seems to be critical for the stability of the cotransporter at 
the brush border membrane, as either preventing the association in cell culture 
models [66] or the absence of NHERF1 in animal models [128] results in a reduced 
expression of NaPi-IIa at the cell membrane. Consistently with this reduction, Nherf1-
/- mice have an increased urinary excretion of phosphate that results in 
hypophosphatemia [128]. In humans, mutations on NHERF1 have been reported in 
patients with hypophosphatemia and relatively low TmP/GFR values [78]. NHERF1 
has the potential to indirectly connect with the actin cytoskeleton via its association 
with Ezrin, suggesting that the anchoring of NaPi-IIa to the plasma membrane 
depends on the formation of a multiprotein complex. Supporting this hypothesis, 
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Ezrin-/- mice have a reduced expression of NHERF1 and NaPi-IIa at the brush border 
membrane that leads to urinary loss of phosphate and hypophosphatemia [60]. 
Therefore, it is not surprising that factors that reduce the expression of NaPi-IIa at the 
brush border membrane (such as PTH, dopamine or FGF23) induce the dissociation 
of NaPi-IIa from NHERF1. Treatment of renal proximal tubular cells with PTH leads to 
phosphorylation of a serine residue (S77) located within the PDZ domain of NHERF1 
involved in interaction with NaPi-IIa. NHERF1 phosphorylation at S77 then results in 
a reduced binding to NaPi-IIa, allowing the retrieval of the cotransporter from the cell 
surface [35,143]. A similar mechanism has been proposed for dopamine [145] and 
FGF23 [144]. PTH and dopamine act at least partially via activation of PKC and/or 
PKA [10,14], and pharmacological activation of either kinase also results in 
phosphorylation of S77 [143]. Recently, PKA was also shown to phosphorylate Ezrin 
in vitro, and this modification reduces the interaction of Ezrin with NHERF1 [150]. 
Phosphorylation of Ezrin may provide an additional molecular mechanism for the 
destabilization of NaPi-IIa at the cell surface upon hormonal activation. NHERF2 has 
been suggested to control the intracellular signaling pathway activated upon binding 
of PTH to its receptor [95]. Thus in the absence of NHERF2, treatment with PTH 
results in activation of PKA whereas the presence of NHERF2 leads preferentially to 
activation of phospholipase C (PLCβ). This switch is based on the capability of 
NHER2 to bind simultaneously to the PTH1R and PLCβ, a feature also shared with 
NHERF1 [95]. Accordingly, mice lacking NHERF1 show impaired activation of PLC 
by luminal PTH receptors and reduced internalization of NaPi-IIa [30]. 
         The PDZ-binding motif of NaPi-IIa is also responsible for binding to Shank2E 
[100,36]. Shank2E also interacts with dynamin II, a GTPase involved in the pinching 
off and endocytosis of clathrin-coated vesicles [107]. Unlike the NHERF proteins, 
Shank2E is internalized together with NaPi-IIa in response to high phosphate, 
suggesting that Shank2E controls the intracellular trafficking of the cotransporter. 
           The interaction of NaPi-IIa with GABARAP (GABA-receptor associated 
protein) is independent of the PDZ-binding motif [116,56]. GABARAP is known to 
interact with proteins involved in intracellular trafficking, including tubulin, the N-
ethylmaleimide-sensitive factor and clathrin (for review see [102]). GABARAP-/- mice 
are characterized by reduced urinary excretion of phosphate associated with 
increased expression of NaPi-IIa; also NHERF1 was found to be upregulated in 
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mutant animals [116]. The increase in NaPi-IIa does not result in higher levels of 
phosphate in plasma, probably due to a reduction in the expression of the intestinal 
NaPi-IIb cotransporter (see below). 
 
Regulation of renal NaPi-IIa and NaPi-IIc 
 
Regulation of SLC34 phosphate transporters has been best defined in the 
case of NaPi-IIa. In general, regulation occurs mostly on the posttranscriptional level 
by altering the rate of synthesis and degradation and by changing the amount of 
NaPi-IIa transporter molecules in the brush border membrane. There is little evidence 
for a regulation of NaPi-IIa transporters by altering their activity in the brush border 
membrane through phosphorylation or other related mechanisms. 
The biosynthetic pathway and mechanisms governing insertion of NaPi-IIa into 
the brush border membrane are little known. NaPi-IIa is N-glycosylated and 
experiments in Xenopus oocytes indicated that lack of glycosylation is not altering 
transport characteristics but decreased membrane expression [62]. Thus, 
glycosylation may be required for insertion into and/or stability in the plasma 
membrane. 
Retrieval of NaPi-IIa from the brush border membrane occurs rapidly within 
minutes after injecting PTH into rodents or after increasing dietary phosphate intake 
[13,24]. NaPi-IIa is internalized via a route involving clathrin-coated pits as well as 
early and late endosomes and is routed to lysosomes for degradation 
[13,81,111,134]. There is no evidence for recycling of internalized NaPi-IIa 
molecules. The pathway of NaPi-IIa internalization is shared with receptor-mediated 
endocytosis occuring in the same cells of the proximal tubule. The integrity of the 
machinery involved in receptor-mediated endocytosis is required for NaPi-IIa 
internalization. Genetic deletion of the major endocytic receptor megalin or its 
chaperone Receptor-Associated Protein (RAP) alters the structure of the subapical 
compartment and reduces steady-state as well as PTH provoked endocytosis leading 
to accumulation of NaPi-IIa in the brush border membrane and enhanced phosphate 
reabsorption [9,11].  
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As indicated above, internalization of NaPi-IIa is initialized by phosphorylation 
of NHERF1 at serine 77 and subsequent dissociation of NaPi-IIa and NHERF1. NaPi-
IIa is internalized whereas NHERF1 and other NaPi-IIa associated proteins remain at 
the apical membrane [35,143]. There is no evidence for phosphorylation of NaPi-IIa 
by parathyroid hormone. The exact molecular mechanisms that address NaPi-IIa to 
the lysosome and are required for its routing are presently unknown. 
In most cases NaPiIIa internalization appears to occur without direct 
modification of the NaPiIIa transporter in the plasma membrane. However, 
downregulation by FGF23-klotho may involve also an additional mechanism. FGF23 -
klotho may induce direct phosphorylation of NHERF1 and internalization of NaPi-IIa 
[5]. In addition, klotho alone may proteolytically degrade NaPi-IIa located in the 
plasma membrane through a beta-glucuronidase-like mechanism. Klotho seems to 
first modify glycan residues on NaPi-IIa, allowing for cleavage of NaPi-IIa inducing its 
lysosomal degradation [69]. 
Regulation of NaPi-IIc abundance and activity is much less well studied. NaPi-
IIc removal from the brush border membrane in response to PTH or intake of 
phosphate-rich diets occurs with much slower kinetics than for NaPi-IIa and requires 
hours [112,127,126]. In contrast to NaPi-IIa, NaPi-IIc may undergo partial recycling 
[126]. 
 
Regulation by signaling networks and kinases 
Activation of parathyroid hormone receptors down-regulate NaPi-IIa 
abundance at the brush border membrane within minutes through at least two 
different signaling pathways involving either PKA or PKC. Both pathways may 
eventually merge in ERK1/2 and lead to the phosphorylation of NHERF1. PTH leads 
also to downregulation of NaPi-IIc, however, this requires hours and the signals 
mediating this effect are not known [112].  
 
The signals mediating the down-regulation of NaPiIIa and NaPi-IIc by FGF-23 
are not fully elucidated. FGF23 signals through binding to the FGF1c and FGF4 
receptors together with its co-ligand klotho to reduce NaPi-IIa and NaPi-IIc protein 
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and mRNA abundance [119,75,124]. FGF1c and klotho are expressed in the 
proximal tubule and with much higher abundance in the distal convoluted tubule. 
Activation of FGF1c causes phosphorylation of FRS2a and ERK1/2 and acts 
downstream on Egr1 [85]. Injection of FGF23 into mice increases staining for 
phosphorylated ERK1/2 in the distal convoluted tubule and it has thus been 
suggested that the distal convoluted tubule may generate signals acting on the 
proximal tubule to reduce phosphate reabsorption [37]. Alternatively, FGF23 may 
directly activate in the proximal tubule a signaling cascade involving sgk1, ERK1/2, 
and NHERF1 phosphorylation to regulate NaPi-IIa [5]. 
 Also activation of guanylate cyclases and increased intracellular cGMP 
production reduces NaPi-IIa expression in the brush border membrane. Atrial 
natriuretic peptide and NO may reduce renal phosphate reabsorption involving cGMP 
dependent retrieval of NaPi-IIa [12]. 
 Little is known about signals involved in the upregulation of NaPi-IIa 
expression and stimulated renal phosphate reabsorption. The insulin-like growth 
factor 1 (IGF1) stimulates NaPi-IIa expression and activity and may mediate some of 
the age and growth dependent effects on renal phosphate handling. The 
phosphorylation and activation of tyrosine kinase may be required for the IGF1- 
dependent effects [74]. 
Various additional kinases are involved in the regulation of NaPi-IIa function as 
evident from gene-modified mouse models. However, it is not clear in all instances if 
this is by directly affecting signaling networks in the proximal tubule or more indirectly 
by primarily altering the regulation of hormones acting on the kidney. A role for 
GSK3, Akt2/protein kinase beta 2, Jak2, Osr1, Spak and Sgk3 has been found 
[108,41,129,109,80]. 
 
Regulation of NaPi-IIb 
           The abundance of NaPi-IIb at the apical membrane of the small intestine is 
under the control of a number of factors. Early studies indicated that phosphate 
absorption across the intestinal epithelia decreases during the suckling-weaning 
transition [23,39,22]. This reduction in the phosphate absorbing capacity coincides 
with an increase in the plasma levels of corticosterone, a glucocorticoid involved in 
16 
 
intestinal maturation [65]. Arima et al found that corticosterone administration results 
in downregulation of NaPi-IIb at the mRNA and protein level [6], an effect that may 
underlay the ontogenic regulation of the cotransporter.  
             As for the renal cotransporters, reduction in dietary intake of phosphate 
results in increased expression of NaPi-IIb in the intestinal epithelia [61]. This 
regulation is most probably independent of 1,25-OH2 vitamin D3, as it is preserved in 
VDR-/- as well as 1αOHase-/- mice [31,123]. There are some discrepancies regarding 
whether or not the dietary adaptation involves changes on NaPi-IIb mRNA 
expression, with reports in favor [123,114] and against [61,31] transcriptional 
regulation. Recently it was shown that NaPi-IIb and NHERF1 are coexpressed in 
intestinal epithelia and that they interact with each other via a C-terminal PDZ-binding 
motif of the cotransporter [55]. Furthermore, the dietary upregulation of NaPi-IIb is 
blunted in NHERF1-/- mice. Improper dietary regulation of the cotransporter has also 
been described in mice deficient for myosin VI [64]. Myosin VI is a minus-end actin-
motor protein involved in a wide range of cellular functions including clathin-mediated 
endocytosis. Hegan et al reported that feeding a low Pi diet results in high and similar 
levels of NaPi-IIb in wild type and myosin VI-/- mice. However, upon administration of 
high phosphate the dowregulation of the cotransporter at the cell surface is smaller in 
myosin VI-/- than wild type mice [64]. These findings suggest that myosin VI is 
required for the membrane retrieval of the cotransporter. In addition to NHERF and 
myosin VI deficient mice, the expression of NaPi-IIb is also altered in GABARAP-/- 
mice. As indicated above, NaPi-IIb expression is reduced in these mice, most 
probably as a compensatory mechanism for the increased expression of the renal 
NaPi-IIa ([117,116]. 
             Although not required for the dietary adaptation, 1,25-OH2 vitamin D3 directly 
upregulates the expression of NaPi-IIb [61]. Moreover, the abundance of NaPi-IIb 
(protein and mRNA) is reduced in the intestinal epithelia of VDR-/- mice [123,31]. 
Experiments in rats indicated that the effect of 1,25-OH2 vitamin D3 on NaPi-IIb 
expression involves changes in mRNA transcription in young but not in adult animals 
[148]. This last report also shows that the activity of the human NaPi-IIb promoter 
increases in response to 1,25-OH2 vitamin D3. The levels of 1,25-OH2 vitamin D3 are 
reduced in patients chronically treated with antimicrobial (rifampicin) or antiepileptic 
(phenobarbital) drugs [28]. Both drugs activate the pregnane X receptor (PXR), a 
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nuclear xenobiotic receptor and ligand-activated transcription factor responsible for 
the inactivation and excretion of drugs. Although the levels of 1,25-OH2 vitamin D3 
seem unaffected in PXR-/- mice, these animals have low serum phosphate levels 
associated with reduced intestinal expression of NaPi-IIb [84]. Furthermore, 
activation of PXR with rifampicin was reported to induce the NaPi-IIb promoter 
activity.  
           Estrogen administration increases the Na/Pi cotransport across the intestinal 
epithelia by upregulating the expression of NaPi-IIb [149]. Estrogens are known to 
regulate the production of 1,25-OH2 vitamin D3 [7]. However their effect on the 
intestinal cotransporter is, at least partially, independent of 1,25-OH2 vitamin D3 as 
the activity of the human NaPi-IIb promoter measured in cell culture is directly 
stimulated by β-estradiol [149]. 
           Normalization of the acid-base status upon metabolic acidosis involves 
an increased urinary excretion of protons. Acidosis leads to the release of phosphate 
from bones as well as to inhibition of renal reabsorption of phosphate, the later 
contributing to the supply of titrable acids in the urine [2,106]. In contrast, both the 
intestinal Na/Pi cotransport and the expression of NaPi-IIb are increased in metabolic 
acidosis [130], suggesting that the gut compensates for the urinary loss of 
phosphate. 
 
Inherited disorders of phosphate transport in the SLC34 family 
Mutations in SLC34A1 and renal phosphate handling 
The role of mutations and gene variants in the SLC34A1 gene on renal 
phosphate handling and kidney function are still not fully understood. Prie and 
colleagues reported on three patients with reduced renal threshold for phosphate 
reabsorption (TmP/GFR < 0.7 mM), hypercalciuria,  and kidney stones. In one patient 
a A48F mutation was detected, in the two other related patients a V147M mutation 
was found. In all three patients only one allele was found mutated and no further data 
were available whether there was cosegregation of the mutation with the phenotype 
in relatives of the patients [113]. Subsequent functional analysis of the mutations did 
not reveal any differences in the functional transport properties of the mutants or their 
trafficking in a mammalian renal cell line [140]. A second report presented patients 
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from a consanginous Arab Isreali family that had rickets, hypophosphatemic Fanconi 
syndrome and hypercalcuria with highly elevated 1,25-OH2 vitamin D3 levels. The 
patients had all a homozygous in-frame duplication (21 bp) G154-V160dup that 
completely abolished phosphate induced currents in the mutant expressed in 
Xenopus laevis oocytes [94]. Since the inserted stretch of amino acids affects a 
putative transmembrane domain of NaPi-IIa it is very likely that the overall structure 
of the transporter is severely altered. The occurrence of the Fanconi syndrome is not 
complete since plasma bicarbonate levels are unchanged and patients are able to 
increase levels of active 1,25-OH2 vitamin D3 [94]. Moreover, in two different mouse 
models of Slc34a1 deficiency either due to genetic deletion or to the spontaneous 
occurrence of the compound heterozygous mutations at L499V and V528M no 
Fanconi syndrome has been observed [15,70]. Thus, our understanding of the 
importance of SLC34A1 for renal phosphate handling in man and the impact of 
mutations on generalized proximal tubule functions is incomplete to date. 
 
Mutations in SL34A2: pulmonary microlithiasis 
 Mutations in SLC34A2 cause pulmonary microlithiasis that is in some cases 
associated with testicular microlithiasis [33]. Different mutations have been described 
including missense mutations and truncations [40]. The cellular mechanisms how 
mutations in SLC34A2 lead to impaired NaPi-IIb function has not been addressed to 
date. Pulmonary alveolar microlithiasis (PAM) is a very rare lung disease 
characterized by calcifications within the alveoli that may eventually lead to loss of 
lung function [40]. The pathogenesis of the disease has not been clarified and may 
relate to functions of NaPi-IIb in alveolar type II cells [133]. Whether NaPi-IIb is 
relevant for removing phosphate from the alveolar fluid or has other functions has not 
been determined. Unfortunately, no information is available whether patients with 
SLC34A2 mutations show other systemic disturbances of phosphate homeostasis 
and whether intestinal phosphate absorption is altered. 
 Mice lacking NaPi-IIb (Slc34a2) are not viable whereas inducible NaPi-IIb KO 
mice with deletion of Slc34a2 in adult mice causes pulmonary calcification and 
reduced intestinal phosphate absorption [118]. Loss of NaPi-IIb is associated with 
abolished sodium-dependent phosphate transport in ileum suggesting that NaPi-IIb is 
the major if not only important phosphate transporter in this segment. However, 
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overall intestinal phosphate absorption was only mildly reduced suggesting that other 
segments of the small and large intestine absorb the largest quantity of phosphate 
and/or that other pathways such as the paracellular route may provide for major 
phosphate fluxes in intestine. 
 
Mutations in SLC34A3: Hereditary hypophosphatemic rickets with 
hypercalcuria (HHRH) 
 
 HHRH is a rare autosomal recessive disorder caused by mutations in the 
SLC34A3 gene encoding for NaPi-IIc [92,19]. Patients suffer from hypophosphatemia 
due to renal phosphate losses. Reduced phosphate availability impairs bone 
mineralization and growth leading to rickets. Compensatory increases in 1,25-OH2 
vitamin D3 synthesis and levels stimulate intestinal phosphate and calcium 
absorption. However, excessive calcium uptake is counterbalanced by increased 
urinary excretion where high urinary levels of calcium and phosphate cause 
nephrolithiasis and nephrocalcinosis.  
 Patients with HHRH showed SLC34A3 deletions and truncations but also 
splice site mutations, homozygous missense or compound missense mutations [18]. 
Missense mutations affect trafficking to the plasma membrane and/or abundance 
[73]. 
 Mice lacking NaPi-IIc have been generated and surprisingly no major 
phenotype could be detected. Renal phosphate handling is similar to wildtype mice 
and no hypophosphatemia or hyperphosphaturia develops. However, NaPi-IIc show 
hypercalciuria and slightly increased 1,25-OH2 vitamin D3 levels [125]. Also a kidney-
specific NaPi-IIc deficient mouse model has been developed and this mouse model 
has normal renal phosphate and calcium handling with no signs for altered 1,25-OH2 
vitamin D3 metabolism (Myakala, Motta, Murer, Wagner, Koesters, Biber, Hernando, 
unpublished results). Thus, while NaPi-IIc has a major role in phosphate metabolism 
in humans, the role in mice appears to be minor. 
 
Summary and future perspectives  
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 Twenty years after the molecular identification of the first member of the 
SLC34 family, much progress has been made in understanding the hormonal 
regulation of these transporters, identification of various interacting proteins, and 
gaining insights into the transport mechanism of these transporters. Genetic studies 
demonstrated that all three transporters have important physiological functions. 
However, major questions have remained unanswered or are only partially 
understood. At least three fields are certainly of major interest and not fully explored 
to date. 
 Structural models of SLC34 transporters rely on structure-functions studies 
mostly using mutagenesis,  chemical labeling and electrophysiology  experiments. 
Obviously, crystal structures of mammalian SLC34 transporters or homologs would 
greatly enhance our understanding of the transport mechanism and would possibly 
facilitate development of isoform specific inhibitors.  
 NaPi-IIa served as a model protein to examine regulation of phosphate and 
other epithelial transporters. The identification of interacting proteins helped to 
understand the role of some of these proteins in epithelial physiology as exemplified 
for NHERF1. Nevertheless, our understanding of the "life cycle" of these transport 
proteins is incomplete.  We miss insight into the processes regulating translation and 
trafficking of transporters to the cell membrane and mechanisms that affect the 
residence at the plasma membrane. 
 A third field that will require further attention is the regulation of these 
transporters by phosphate. This is also of major clinical importance as dysregulation 
of phosphate handling by intestine, bone, and kidney may contribute to chronic 
kidney disease, bone disease, and subsequently may increase the risk for 
cardiovascular diseases. FGF23 has gained much attention over the last years but 
the mechanisms how increases in phosphate intake or body content trigger changes 
in major phosphate regulating hormones such as parathyroid hormone, FGF23 or 
1,25-OH2 vitamin D3 are largely unknown. The possibility that phosphate may 
regulate these transporters also independent from known factors remains also open. 
Thus, "phosphate-sensing" mechanisms and mediators of regulation are not fully 
explored and understood. 
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FIGURES 
 
Figure 1. Localization of renal phosphate cotransporters in rodent kidney 
In kidney, at least three Na+-dependent phosphate cotransporters are involved in 
phosphate reabsorption: the two SLC34 family members NaPi-IIa and NaPi-IIc and 
the SLC20 family member Pit-2. The upper panels shows localization of the three 
transporters in the murine kidney cortex of animals kept on a low phosphate diet. The 
nephron models depict localization of the three transporter under conditions of 
normal-high phosphate intake (red shaded parts) which is restricted to the initial S1 
segment of proximal tubules of juxtamedullary nephrons. During phosphate 
depletion, expression of all three transporters spreads to proximal tubules of 
superficial nephrons and NaPi-IIa expression extends also to S2 and S3 segments of 
the proximal tubule (yellow shaded nephron segments).   
 
 
Figure 2. Transport mechanism of SLC34 proteins 
 
For all SLC34 proteins, transmembrane transport for an inwardly directed Na+ 
gradient, comprises an ordered sequence of binding steps in which 2 Na+ ions in the 
extracellular medium bind sequentially, followed by divalent Pi and a third Na+ ion. 
Cartoons indicate two conformations of the protein. Substrate release to the cytosol 
occurs after reorientation of the fully loaded carrier. For electrogenic NaPi-IIa and 
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NaPi-IIb (top), an intrinsic negative charge (hypothesized to be a conserved aspartic 
acid located between the 3rd and 4th predicted transmembrane spanning regions (Fig. 
3) and which senses the transmembrane field), confers voltage dependence to 
transport cycle. This allows binding of the 1st Na+ ion (1) within the transmembrane 
electric field and subsequent translocation together with the other substrates (2,3,4), 
giving a 3:1 Na+:Pi stoichiometry. When substrates are released to the cytosol, the 
intrinsic charge senses the transmembrane field, which leads to a voltage-dependent 
reorientation of the empty carrier, ready for the next transport cycle. The 
electroneutral NaPi-IIc (bottom), which conserved glycine instead of aspartic acid at 
the critical site , has one Na+ ion bound (1) (like NaPi-IIa/b), but cannot be 
translocated [53], thus resulting in a 2:1 Na+:Pi transport stoichiometry. In the 
absence of phosphate, NaPi-IIa/b show a Na+-dependent leak mode, hypothesized to 
involve the translocation of the 1st Na+ ion [3]. Cartoons modified from [47]. 
 
 
Figure 3. Topology and structure-function features of SLC 34 proteins  
Topology model for SLC34 show the predicted transmembrane domains (numbered) 
and repeat regions (dark shading) for each family. The 3-D folding is currently 
unknown. For SLC34 evidence suggests that the reentrant regions (3,4) and (8,9) 
physically associate to form a substrate coordination site [52]. The disulfide bridge 
and two glycosylation sites in the large extracellular loop are indicated for the SLC34 
proteins. Critical residues for targeting/regulation and electrogenicity are highlighted. 
 
 
Figure 4. Network of proteins interacting with NaPi-IIa in renal proximal tubule 
cells 
NaPi-IIa interacts with the four members of the NHERF family as well as with Shank 
in the brush border membrane. These interactions take place between the C-terminal 
PDZ-binding motif of NaPi-IIa (TRL) and the PDZ domains of the NHERFs/Shank 
proteins indicated with an asterisk.  Association with NHERF1/2 controls the stability 
of the cotransporter in the apical membrane. In addition, NHERF1/2 may play a role 
in the PTH-induced downregulation of NaPi-IIa by determining the intracellular 
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signaling activated upon receptor stimulation. The physiological meaning of the 
association of NaPi-IIa with NHERF3/4 is less clear and it is not discussed in this 
review. In addition to a PDZ-domain, Shank2E also contains ankyrin repeats as well 
as SH3 and prolin-rich domains that are not shown in the Figure. PTH-R: PTH 
receptor; PLC: phospholipase C; PDZ: post-synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dlg1) and Zonula occludens (ZO-1). MERM-
BD: merlin-ezrin-radixin-moesin-binding domain.  
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